Eagle Pharmaceuticals v. Slayback & Apotex: Federal Circuit Affirms Bendamustine Patent Unpatentable
Eagle Pharmaceuticals appealed a district-level ruling that US11103483B2 — its patent covering bendamustine formulation technology — was unpatentable. The Federal Circuit affirmed in a Rule 36 judgment, ending Eagle’s enforcement effort against generic challengers Slayback Pharma and Apotex after 440 days of appellate proceedings.
Federal Circuit ends Eagle’s bendamustine patent battle with Rule 36 affirmance
Eagle Pharmaceuticals, Inc. filed this appeal at the Court of Appeals for the Federal Circuit on 2 November 2022, challenging a lower-court determination that US11103483B2 — a patent directed to formulations of bendamustine, an alkylating agent used in haematological cancer treatment — was unpatentable. Eagle named Slayback Pharma LLC, Apotex Corp., and Apotex Inc. as defendants, all of which are generic pharmaceutical companies that had sought to market competing bendamustine products.
The Federal Circuit closed the case on 16 January 2024 by issuing a judgment under Federal Circuit Rule 36, affirming the lower tribunal’s ruling without a written opinion. The Rule 36 affirmance carries the same legal force as a reasoned decision: the court found no reversible error in the finding that the asserted patent claims are unpatentable, and the lower ruling stands in full. Eagle’s patent is therefore unenforceable against the named defendants.
The 440-day duration from filing to disposition is consistent with contested ANDA-related pharmaceutical patent appeals before the Federal Circuit. Because Rule 36 was applied, no written analysis of the unpatentability grounds was published, leaving the specific legal rationale — whether obviousness, anticipation, or another basis — not publicly articulated at the appellate level. This limits downstream visibility into which claim elements were decisive, a factor of significance for Eagle’s remaining patent portfolio and for generic entrants monitoring enforcement risk.
Filing to affirmance in 440 days
440-day appellate proceeding — above the Federal Circuit median for ANDA pharma appeals
Federal Circuit affirms: what the Rule 36 ruling means for both parties
Rule 36 affirmance: the lower decision stands, no written opinion
A Federal Circuit Rule 36 judgment affirms the decision below without a written opinion when the court finds no reversible error. The affirmance carries full precedential weight for the parties: the finding that US11103483B2 is unpatentable is now conclusively upheld. Critically, no new appellate reasoning is published, so the specific legal basis for unpatentability is not elaborated at this level.
No reversible error foundEagle loses enforcement: the patent cannot be asserted against these defendants
With the unpatentability ruling affirmed, Eagle Pharmaceuticals cannot enforce US11103483B2 against Slayback Pharma, Apotex Corp., or Apotex Inc. The patent’s validity is compromised at the appellate level, materially weakening its exclusivity position in the bendamustine formulation space. Eagle’s options — en banc rehearing or Supreme Court certiorari — face high procedural bars and low statistical success rates.
Patent unenforceable vs. defendantsSlayback and Apotex cleared: generic bendamustine path substantially de-risked
Slayback Pharma and the Apotex entities secured affirmance of the unpatentability finding, substantially clearing the IP risk from US11103483B2 for their respective bendamustine product programmes. This affirmance strengthens their regulatory and commercial position. Other generic entrants not party to this litigation may also benefit from the persuasive weight of the unpatentability determination, though they are not formally bound by this judgment.
Generic path de-riskedBendamustine formulation competition intensifies as patent barrier falls
The Federal Circuit’s affirmance suggests the bendamustine formulation space faces reduced patent barriers, consistent with increased generic competition and downward pricing pressure on branded products. Companies holding similar formulation patents in oncology should audit claim scope in light of the unpatentability finding. The absence of a written opinion, however, means the precise doctrinal risk factor — whether excipient selection, concentration ratios, or stability data was decisive — remains commercially opaque.
Increased generic competition riskFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Eagle Pharmaceuticals, Inc. | Company | Specialty pharmaceutical company — holder of US11103483B2, bendamustine formulationsSearch in Eureka ↗ |
| Defendant | Slayback Pharma, LLC | Company | Generic pharmaceutical challengers: Slayback Pharma LLC, Apotex Corp., and Apotex Inc.Search in Eureka ↗ |
| Co-Defendant | Apotex Corp. | Company | Search in Eureka ↗ |
| Co-Defendant | Apotex, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Daniel Brown | Attorney | Counsel for Eagle Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | David Kowalski | Attorney | Counsel for Eagle Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Gabriel K. Bell | Attorney | Counsel for Eagle Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Gregory G. Garre | Attorney | Counsel for Eagle Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Michael Clemente | Attorney | Counsel for Eagle Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Latham & Watkins, LLP | Law Firm | Representing Eagle Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Constance Huttner | Attorney | Counsel for Slayback Pharma, LLCSearch in Eureka ↗ |
| Defendant counsel | Jason Aaron Lief | Attorney | Counsel for Slayback Pharma, LLCSearch in Eureka ↗ |
| Defendant law firm | Windels Marx Lane & Mittendorf, LLP | Law Firm | Representing Slayback Pharma, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The judgment reads: ‘AFFIRMED. See Fed. Cir. R. 36.’ This terse disposition reflects the Federal Circuit’s practice of issuing summary affirmances when a panel unanimously agrees the lower tribunal committed no reversible error and that a written opinion would add no precedential value. For Eagle, this forecloses appellate correction of the unpatentability finding. For Slayback and Apotex, the affirmance is legally equivalent to a full reasoned decision upholding their position — the absence of written reasoning does not diminish its binding effect between these parties.
US11103483B2 — Bendamustine pharmaceutical formulations
US11103483B2, filed under application number US16/509920, claims formulations of bendamustine — an alkylating agent widely used in the treatment of chronic lymphocytic leukaemia and indolent B-cell non-Hodgkin lymphoma. Formulation patents in this class typically protect specific combinations of solvent, stabiliser, or concentration parameters that differentiate a branded product from earlier compositions. The patent’s claims were found unpatentable by the lower tribunal, a finding now affirmed by the Federal Circuit.
Bendamustine is an established cytotoxic agent with a genericised active ingredient, making formulation patents a critical layer of exclusivity for branded manufacturers. US11103483B2 represented Eagle Pharmaceuticals’ attempt to maintain that exclusivity against Slayback and Apotex’s generic programmes. The affirmed unpatentability ruling signals that the formulation differentiation claimed was insufficient to satisfy patentability requirements — a commercially significant outcome for any competitor monitoring Eagle’s bendamustine IP position or planning entry into this drug class.
Should you run an FTO against US11103483B2?
Any pharmaceutical company developing, manufacturing, or seeking ANDA approval for bendamustine formulations should note that US11103483B2 has been held unpatentable and that holding has been affirmed by the Federal Circuit. While this substantially reduces infringement risk from this specific patent against the named defendants, organisations not party to this case should independently verify their freedom-to-operate position — the judgment binds only the parties named in Case No. 23-1110. Eagle may hold related formulation patents not adjudicated here.
PatSnap Eureka’s FTO Search Agent can map Eagle Pharmaceuticals’ full bendamustine-related patent portfolio, identify claims that survive this ruling, flag pending applications that could mature into enforceable rights, and surface prior art relevant to any remaining validity challenges. For R&D and regulatory teams preparing ANDA filings or formulation development programmes in the bendamustine space, this analysis is a critical pre-investment step.
Run a freedom-to-operate analysis on US11103483B2 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit ANDA appeals involving pharmaceutical formulation patents
Explore Federal Circuit cases involving ANDA challenges to pharmaceutical formulation patents, including Rule 36 affirmances and unpatentability findings in oncology drug classes.
What this case signals for the pharmaceutical formulation IP landscape
A Rule 36 affirmance on unpatentability in an oncology drug formulation case carries pointed lessons for branded pharma IP strategy and generic entry timing.
Rule 36 affirmances leave no doctrinal record — plan for that opacity
When the Federal Circuit affirms via Rule 36, no written opinion is published. Patent holders and generic challengers in adjacent bendamustine or oncology formulation disputes cannot mine this ruling for specific claim construction or obviousness reasoning. Affected parties should rely on the lower-level record and analogous written decisions rather than this judgment for legal strategy.
Unpatentability findings at the Federal Circuit elevate risk for related formulation patents
An affirmed unpatentability ruling on a bendamustine formulation patent suggests that patent examiners, IPR panels, or district courts may apply heightened scrutiny to similar formulation claims in oncology. Branded pharmaceutical companies with portfolios anchored in formulation patents — particularly those relying on excipient or solubility innovations — should conduct proactive validity audits before litigation arises.
Eagle v Slayback — key questions answered
The Federal Circuit affirmed the lower court’s finding that US11103483B2 — Eagle Pharmaceuticals’ patent covering bendamustine formulations — is unpatentable. The court issued its judgment under Federal Circuit Rule 36, meaning no written opinion was published. The case closed on 16 January 2024.
A Rule 36 affirmance means the Federal Circuit found no reversible error in the lower decision and affirmed it without a written opinion. It carries the same legal force as a full opinion for the parties: the unpatentability finding against US11103483B2 is conclusively upheld. Eagle cannot enforce this patent against Slayback Pharma, Apotex Corp., or Apotex Inc.
US11103483B2 (application no. US16/509920) is a patent held by Eagle Pharmaceuticals covering formulations of bendamustine, an alkylating agent used to treat chronic lymphocytic leukaemia and B-cell non-Hodgkin lymphoma. The patent was found unpatentable at the lower level and that finding was affirmed by the Federal Circuit in January 2024.
The Federal Circuit’s judgment directly binds only the named parties — Eagle Pharmaceuticals, Slayback Pharma LLC, Apotex Corp., and Apotex Inc. Other generic manufacturers not party to this case are not formally bound, but may cite the affirmed unpatentability finding as persuasive authority in their own ANDA proceedings or validity challenges against US11103483B2 or related Eagle patents.
Federal Circuit Rule 36 allows the court to affirm a lower decision without a written opinion when the panel unanimously agrees that no reversible error occurred and that a written opinion would not add precedential value. Its use here means the specific legal grounds for unpatentability — whether obviousness, anticipation, or another doctrine — were not elaborated at the appellate level, limiting downstream doctrinal guidance for the industry.
PatSnap Eureka searches patents and litigation data to answer instantly.